{
    "code": "52027107",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027107",
    "time": "2017-05-12 03:30:56",
    "許可證字號": "衛部藥輸字第027107號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/04\/05",
    "發證日期": "106\/04\/05",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202710702",
    "中文品名": "怡諾肯注射劑",
    "英文品名": "Irinotecan Mylan",
    "適應症": "晚期性大腸直腸癌之第一線治療藥物：-與5-FU及Folinic acid合併，使用於未曾接受過化學治療之患者。-單獨使用於曾接受5-FU療程治療無效之患者。-與cetuximab併用，治療曾接受含irinotecan之細胞毒性療法治療失敗且具有上皮生長因子接受體（EGFR）表現型KRAS野生型轉移性大腸直腸癌患者。-與5-FU、folinic acid及bevacizumab合併治療，做為轉移性大腸癌或直腸癌患者的第一線治療藥物。-與capecitabine合併治療，做為轉移性大腸直腸癌患者的第一線治療藥物。",
    "劑型": "27D注射液劑",
    "包裝": "2、5毫升玻璃小瓶裝 100支以下盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "IRINOTECANHYDROCHLORIDETRIHYDRATE"
    ],
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "6201118216  台灣邁蘭有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F200921000  MYLAN LABORATORIES LIMITED-OTL",
        "製造廠廠址": "PLOT NO. 284B, BOMMASANDRA-JIGANI LINK ROAD, INDUSTRIAL AREA, ANEKAL TALUK, BANGALORE-560105, INDIA",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200037710",
            "成分名稱": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
            "含量描述": "",
            "含量": "0.0200000000",
            "單位": "GM"
        }
    ],
    "仿單外盒": [
        {
            "title": "Irinotecan Mylan中文仿單-106-05-03.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027107&Seq=001&Type=9"
        },
        {
            "title": "Irinotecan Mylan外盒標籤-106-05-03.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027107&Seq=002&Type=8"
        },
        {
            "title": "Irinotecan Mylan中文標籤-106-05-03.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027107&Seq=001&Type=8"
        }
    ]
}